SpringWorks Therapeutics Inc (SWTX)
36.52
+1.81
(+5.21%)
USD |
NASDAQ |
Nov 14, 16:00
36.55
+0.03
(+0.08%)
After-Hours: 20:00
SpringWorks Therapeutics Research and Development Expense (Quarterly): 44.36M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 44.36M |
| March 31, 2024 | 53.62M |
| December 31, 2023 | 43.65M |
| September 30, 2023 | 37.45M |
| June 30, 2023 | 35.86M |
| March 31, 2023 | 33.52M |
| December 31, 2022 | 37.93M |
| September 30, 2022 | 36.07M |
| June 30, 2022 | 38.02M |
| March 31, 2022 | 34.10M |
| December 31, 2021 | 29.34M |
| September 30, 2021 | 22.87M |
| Date | Value |
|---|---|
| June 30, 2021 | 32.09M |
| March 31, 2021 | 17.38M |
| December 31, 2020 | 15.26M |
| September 30, 2020 | 13.92M |
| June 30, 2020 | 12.95M |
| March 31, 2020 | 9.727M |
| December 31, 2019 | 12.17M |
| September 30, 2019 | 10.74M |
| June 30, 2019 | 11.20M |
| March 31, 2019 | 8.423M |
| December 31, 2018 | 3.706M |
| September 30, 2018 | 3.406M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.727M
Minimum
Mar 2020
53.62M
Maximum
Mar 2024
29.49M
Average
33.52M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Ocugen Inc | 8.108M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |
| Theriva Biologics Inc | 2.953M |